(en) Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE. et al. « Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist » J Pharmacol Exp Ther. 2005;315(3):1278–87. Consultable sur : http://jpet.aspetjournals.org/content/315/3/1278.full.pdf
biomedcentral.com
bmcpsychiatry.biomedcentral.com
Soohyun Joe, Jangho Park, Jongseok Lim, Choongman Park & Joonho Ahn, « Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report », BMC Psychiatry, (lire en ligne)
(en) Laurence Brunton, Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th Edition, China, McGraw-Hill, , 2084 p. (ISBN978-0-07-162442-8, BNF42408664), p. 406–410.
books.google.com
(en) Peter Haddad, Peter M. Haddad, Serdar Dursun, Bill Deakin, Adverse symptoms and Psychiatric drugs, Oxford medical publications (lire en ligne), p. 207
cambridge.org
journals.cambridge.org
(en) Newman-Tancredi A, Heusler P, Martel J-C, Ormière A-M, Leduc N, Cussac D. « Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells » The International Journal of Neuropsychopharmacology 2008;11(03):293–307. Consultable sur http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=1819032
cochrane.org
(en) Hirsch LE, Pringsheim T, « Aripiprazole for autism spectrum disorders (ASD) », cochrane.org, (lire en ligne)
(en) Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S., « Second-generation antipsychotics for major depressive disorder and dysthymia. », Cochrane Database Syst Rev, vol. 12, no 6, , CD008121. (PMID21154393, DOI10.1002/14651858.CD008121.pub2)
(en) Fava M, Dording CM, Baker RA, Mankoski R, Tran QV, Forbes RA, Eudicone JM, Owen R, Berman RM, « Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. », Prim Care Companion CNS Disord., vol. 11, no 1, , pii: PCC.10m00994. (PMID21731833, DOI10.4088/PCC.10m00994gre)
Laura Vrignaud, Jerémie Aouille, Michel Mallaret et Geneviève Durrieu, « [Hypersexuality associated with aripiprazole: a new case and review of the literature] », Therapie, vol. 69, no 6, , p. 525–527 (ISSN0040-5957, PMID25293487, DOI10.2515/therapie/2014064, lire en ligne, consulté le )
(en) Maren Carbon, John M. Kane, Stefan Leucht et Christoph U. Correll, « Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis », World Psychiatry, vol. 17, no 3, , p. 330–340 (ISSN2051-5545, PMID30192088, PMCIDPMC6127753, DOI10.1002/wps.20579, lire en ligne, consulté le )
(en) Kranzler, Henry R. et al., « Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol », Alcoholism: Clinical and Experimental Research, vol. 32 issue=4, , p. 573–579 (PMID18261195, PMCID3159685, DOI10.1111/j.1530-0277.2007.00608.x)
(en) Konstantin Voronin, Patrick Randall, Hugh Myrick, Raymond Anton, « Aripiprazole Effects on Alcohol Consumption and Subjective Reports in a Clinical Laboratory Paradigm: Possible Influence of Self-Control », Alcoholism: Clinical and Experimental Research, vol. 32, no 11, , p. 1954–1961 (PMID18782344, PMCID2588475, DOI10.1111/j.1530-0277.2008.00783.x)
(en) FC Starrenburg et JP Bogers, « How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins », European Psychiatry, Elsevier, vol. 24, no 3, , p. 164–70 (PMID19285836, DOI10.1016/j.eurpsy.2009.01.001)
(en) Lawler CP. et al., « Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes », Neuropsychopharmacology, vol. 20, no 6, , p. 612–27 (PMID10327430, DOI10.1016/S0893-133X(98)00099- 2)
(en) Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR, « Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist », J Pharmacol Exp Ther, vol. 315, no 3, , p. 1278–87 (PMID16135699, DOI10.1124/jpet.105.092155)
(en) Jordan, S. et al., « The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor », Eur J Pharmacol, vol. 441, no 3, , p. 137–140 (PMID12063084, DOI10.1016/S0014-2999(02)01532-7)
(en) Shapiro, DA. et al., « Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology », Neuropsychopharmacology, vol. 28, no 8, , p. 1400–1411 (PMID12784105, DOI10.1038/sj.npp.1300203)
(en) Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J, « Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms », Biochem Pharmacol, vol. 71, no 4, , p. 521–9 (PMID16336943, DOI10.1016/j.bcp.2005.11.007)
(en) Kegeles LS. et al., « Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride », Neuropsychopharmacology, vol. 33, no 13, , p. 3111–3125 (PMID18418366, DOI10.1038/npp.2008.33)
(en) Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF, « Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride », Neuropsychopharmacology, vol. 27, no 2, , p. 248–59 (PMID12093598, DOI10.1016/S0893-133X(02)00304-4)
(en) Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL, « Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo », Psychopharmacology, vol. 205, no 1, , p. 119–28 (PMID19337725, PMCID2821721, DOI10.1007/s00213-009-1521-8)
Andrew J. Cutler, Ronald N. Marcus, Sterling A. Hardy et Amy O'Donnell, « The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia », CNS spectrums, vol. 11, no 9, , p. 691–702; quiz 719 (ISSN1092-8529, PMID16946694, DOI10.1017/s1092852900014784, lire en ligne, consulté le )
Laura Vrignaud, Jerémie Aouille, Michel Mallaret et Geneviève Durrieu, « [Hypersexuality associated with aripiprazole: a new case and review of the literature] », Therapie, vol. 69, no 6, , p. 525–527 (ISSN0040-5957, PMID25293487, DOI10.2515/therapie/2014064, lire en ligne, consulté le )
(en) Maren Carbon, John M. Kane, Stefan Leucht et Christoph U. Correll, « Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis », World Psychiatry, vol. 17, no 3, , p. 330–340 (ISSN2051-5545, PMID30192088, PMCIDPMC6127753, DOI10.1002/wps.20579, lire en ligne, consulté le )
Andrzej Leś, Katarzyna Badowska-Rosłonek, Marta Łaszcz et Agata Kamieńska-Duda, « Optimization of aripiprazole synthesis », Acta Poloniae Pharmaceutica, vol. 67, no 2, , p. 151–157 (ISSN0001-6837, PMID20369792, lire en ligne, consulté le )
Andrew J. Cutler, Ronald N. Marcus, Sterling A. Hardy et Amy O'Donnell, « The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia », CNS spectrums, vol. 11, no 9, , p. 691–702; quiz 719 (ISSN1092-8529, PMID16946694, DOI10.1017/s1092852900014784, lire en ligne, consulté le )
nih.gov
ncbi.nlm.nih.gov
(en) Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC, « Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes », Cochrane database of systematic reviews (Online), no 3, , p. CD008121 (PMID23554581)
(en) Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S, « Second-generation antipsychotics for major depressive disorder and dysthymia », Cochrane database of systematic reviews (Online), no 12, , p. CD008121 (PMID21154393)
(en) David L. Dunner, Kimberly K. Laubmeier, George Manos, Robert A. Forbes, Ross A. Baker et Robert M. Berman, « Beneficial Effects of Adjunctive Aripiprazole in Major Depressive Disorder Are Not Dependent on Antidepressant Therapy History: A Post Hoc Analysis of 3 Randomized, Double-Blind, Placebo-Controlled Trials », Prim Care Companion CNS Disord, vol. 14, no 6, , p. CD008121 (PMID3622536)
(en) Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A, « The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. », Prim Care Companion CNS Disord, vol. 68, no 6, , p. 843-53 (PMID17592907)
(en) Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S., « Second-generation antipsychotics for major depressive disorder and dysthymia. », Cochrane Database Syst Rev, vol. 12, no 6, , CD008121. (PMID21154393, DOI10.1002/14651858.CD008121.pub2)
(en) Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, Carson W, Baker RA, Marcus RN., « Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. », Neuropsychiatr Dis Treat., no 7), , p. 303-12 (PMID21655344)
(en) Fava M, Wisniewski SR, Thase ME, Baker RA, Tran QV, Pikalov A, Yang H, Marcus RN, Berman RM, « Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. », J Clin Psychopharmacol, vol. 29, no 4, , p. 362-7 (PMID19593176)
(en) Nelson JC, Thase ME, Trivedi MH, Fava M, Han J, Van Tran Q, Pikalov A, Qi Y, Carlson BX, Marcus RN, Berman RM., « Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163) », Prim Care Companion J Clin Psychiatry, vol. 11, no 6, , p. 344-52 (PMID20098527)
(en) Fava M, Dording CM, Baker RA, Mankoski R, Tran QV, Forbes RA, Eudicone JM, Owen R, Berman RM, « Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. », Prim Care Companion CNS Disord., vol. 11, no 1, , pii: PCC.10m00994. (PMID21731833, DOI10.4088/PCC.10m00994gre)
Laura Vrignaud, Jerémie Aouille, Michel Mallaret et Geneviève Durrieu, « [Hypersexuality associated with aripiprazole: a new case and review of the literature] », Therapie, vol. 69, no 6, , p. 525–527 (ISSN0040-5957, PMID25293487, DOI10.2515/therapie/2014064, lire en ligne, consulté le )
(en) Maren Carbon, John M. Kane, Stefan Leucht et Christoph U. Correll, « Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis », World Psychiatry, vol. 17, no 3, , p. 330–340 (ISSN2051-5545, PMID30192088, PMCIDPMC6127753, DOI10.1002/wps.20579, lire en ligne, consulté le )
Andrzej Leś, Katarzyna Badowska-Rosłonek, Marta Łaszcz et Agata Kamieńska-Duda, « Optimization of aripiprazole synthesis », Acta Poloniae Pharmaceutica, vol. 67, no 2, , p. 151–157 (ISSN0001-6837, PMID20369792, lire en ligne, consulté le )
(en) Kranzler, Henry R. et al., « Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol », Alcoholism: Clinical and Experimental Research, vol. 32 issue=4, , p. 573–579 (PMID18261195, PMCID3159685, DOI10.1111/j.1530-0277.2007.00608.x)
(en) Konstantin Voronin, Patrick Randall, Hugh Myrick, Raymond Anton, « Aripiprazole Effects on Alcohol Consumption and Subjective Reports in a Clinical Laboratory Paradigm: Possible Influence of Self-Control », Alcoholism: Clinical and Experimental Research, vol. 32, no 11, , p. 1954–1961 (PMID18782344, PMCID2588475, DOI10.1111/j.1530-0277.2008.00783.x)
(en) FC Starrenburg et JP Bogers, « How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins », European Psychiatry, Elsevier, vol. 24, no 3, , p. 164–70 (PMID19285836, DOI10.1016/j.eurpsy.2009.01.001)
(en) Nguyen CT, Rosen JA, Bota RG. « Aripiprazole Partial Agonism at 5-HT2C: A Comparison of Weight Gain Associated With Aripiprazole Adjunctive to Antidepressants With High Versus Low Serotonergic Activities » Prim Care Companion CNS Disord. [Internet]. 2012;14(5). Consultable sur : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583771/
(en) Lawler CP. et al., « Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes », Neuropsychopharmacology, vol. 20, no 6, , p. 612–27 (PMID10327430, DOI10.1016/S0893-133X(98)00099- 2)
(en) Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR, « Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist », J Pharmacol Exp Ther, vol. 315, no 3, , p. 1278–87 (PMID16135699, DOI10.1124/jpet.105.092155)
(en) Jordan, S. et al., « The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor », Eur J Pharmacol, vol. 441, no 3, , p. 137–140 (PMID12063084, DOI10.1016/S0014-2999(02)01532-7)
(en) Shapiro, DA. et al., « Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology », Neuropsychopharmacology, vol. 28, no 8, , p. 1400–1411 (PMID12784105, DOI10.1038/sj.npp.1300203)
(en) Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J, « Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms », Biochem Pharmacol, vol. 71, no 4, , p. 521–9 (PMID16336943, DOI10.1016/j.bcp.2005.11.007)
(en) Kegeles LS. et al., « Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride », Neuropsychopharmacology, vol. 33, no 13, , p. 3111–3125 (PMID18418366, DOI10.1038/npp.2008.33)
(en) Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF, « Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride », Neuropsychopharmacology, vol. 27, no 2, , p. 248–59 (PMID12093598, DOI10.1016/S0893-133X(02)00304-4)
(en) Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL, « Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo », Psychopharmacology, vol. 205, no 1, , p. 119–28 (PMID19337725, PMCID2821721, DOI10.1007/s00213-009-1521-8)
Andrew J. Cutler, Ronald N. Marcus, Sterling A. Hardy et Amy O'Donnell, « The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia », CNS spectrums, vol. 11, no 9, , p. 691–702; quiz 719 (ISSN1092-8529, PMID16946694, DOI10.1017/s1092852900014784, lire en ligne, consulté le )
Laura Vrignaud, Jerémie Aouille, Michel Mallaret et Geneviève Durrieu, « [Hypersexuality associated with aripiprazole: a new case and review of the literature] », Therapie, vol. 69, no 6, , p. 525–527 (ISSN0040-5957, PMID25293487, DOI10.2515/therapie/2014064, lire en ligne, consulté le )
(en) A J Goudie, J C Cole, « Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications », pubmed.gov, (lire en ligne)
(en) Maren Carbon, John M. Kane, Stefan Leucht et Christoph U. Correll, « Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis », World Psychiatry, vol. 17, no 3, , p. 330–340 (ISSN2051-5545, PMID30192088, PMCIDPMC6127753, DOI10.1002/wps.20579, lire en ligne, consulté le )